<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355822</url>
  </required_header>
  <id_info>
    <org_study_id>PETN_ESTG</org_study_id>
    <nct_id>NCT01355822</nct_id>
  </id_info>
  <brief_title>Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies</brief_title>
  <official_title>Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies: a Prospective Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnancies resulting in IUGR and also in preeclampsia are strongly associated with typical
      underlying placental pathology revealing small placentas and maldevelopment of the decidual
      blood vessels, suggesting under-perfusion from the maternal circulation. Since nitric oxide
      (NO) donors can improve decreased uteroplacental perfusion without any negative effects on
      fetal circulation, these may prevent negative pregnancy outcomes in patients at risk.

      The aim of this study is to evaluate the effectiveness of the long-lasting NO donor
      pentarythrithyltetranitrate (PETN) to reduce the likelihood of adverse pregnancy outcomes
      (intrauterine growth retardation / IUGR, perinatal death, placental abruption, and preterm
      delivery) in women recognized to be at risk for this outcome by abnormal uterine flow in mid
      gestation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of perinatal death and/or IUGR defined as birth weight below the 10th percentile</measure>
    <time_frame>19 -40 weeks of gestation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of IUGR and severe IUGR defined as birth weight below the 5th percentile</measure>
    <time_frame>19-40 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth before completed 37 weeks of gestation and very early preterm birth before completed 32 weeks of gestation</measure>
    <time_frame>19 - 32 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of preeclampsia</measure>
    <time_frame>19 - 40 weeks of gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any form of placental abruption</measure>
    <time_frame>19 - 40 weeks of gestation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>High Risk Pregnancy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PETN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentalong, Actavis Germay: 80 mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PETN</intervention_name>
    <description>Pentaerythrithyltetranitrate: 80 mg orally twice a day</description>
    <arm_group_label>PETN</arm_group_label>
    <other_name>Pentalong®, , Actavis Germany, Langenfeld, Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>orally, twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women 190 to 236 weeks of gestation

          -  abnormal uterine Doppler as defined by bilateral notching, unilateral notching and
             increased impedance with mean resistance index (RI) &gt; 0.65 or with mean RI &gt; 0.7
             without notching at time of enrollement

          -  informed consent

        Exclusion Criteria:

          -  multiple gestation

          -  documented chromosomal or major fetal abnormalities

          -  rupture of membranes and/or clinical chorioamnionitis at time of enrolment

          -  maternal disease defined as contraindication for intake of PETN
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Jena, Department of Obstetrics</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2011</study_first_posted>
  <last_update_submitted>May 26, 2011</last_update_submitted>
  <last_update_submitted_qc>May 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Ekkehard Schleußner</name_title>
    <organization>University Hospital Jena, Deartmet og Obstetrics</organization>
  </responsible_party>
  <keyword>abortion</keyword>
  <keyword>perinatal death</keyword>
  <keyword>IUGR</keyword>
  <keyword>preterm birth</keyword>
  <keyword>placental abruption</keyword>
  <keyword>preeclampsia</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

